# Get Tirzepatide — A Gilded Cabinet of the Tirzepatide Evidence > The tirzepatide clinical record, set in baroque cabinets: dual GIP/GLP-1 agonism, SURPASS and SURMOUNT outcomes, half-life and titration, and the boxed-warning record. Editorial; not medical advice. ## Cabinet Zero — Opening Plate **Tirzepatide, Set in Gilded Frames.** An ornate editorial chronicle of a dual GIP and GLP-1 receptor agonist whose clinical record, by 2026, comprises more than a dozen named phase-three trials. Read it as a gallery — one cabinet for the molecule, one for the trials, one for dose, one for caveat. - Trials: 15+ - Participants: 13,000+ - Peak weight loss: 22.5% - Half-life: ~5 days ## A molecule worth the ceremony Tirzepatide is a thirty-nine-amino-acid peptide that engages two receptors at once — the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) — and does so with a deliberately uneven hand. Its affinity at the GIP receptor is roughly equivalent to that of native GIP; its affinity at the GLP-1 receptor is approximately five-fold weaker than native GLP-1 [4]. That asymmetry, together with a biased mode of GLP-1R signaling that favors cyclic-AMP generation over beta-arrestin recruitment, is the pharmacological signature on which the entire clinical programme is built. The peptide is stabilised at positions two and thirteen by α-aminoisobutyric acid (Aib) substitutions, which resist cleavage by dipeptidyl peptidase-4 and other proteases, and it is anchored to a C20 fatty diacid moiety that drives ninety-nine percent albumin binding [5]. The result is a mean elimination half-life of approximately five days in humans and a subcutaneous bioavailability of approximately eighty percent — figures that together justify a once-weekly dosing cadence rather than the more frequent regimens of earlier incretin therapeutics [5]. - CAS: 2023788-19-2 - Formula: C225H348N48O68 - Molecular weight: 4810.52 Da - Aib substitutions: positions 2 and 13 ## What the clinical record actually says Tirzepatide carries one of the densest randomised-trial records of any peptide therapeutic in recent memory. In SURPASS-1, monotherapy at five, ten, and fifteen milligrams once weekly reduced glycated haemoglobin (HbA1c) by 1.87 to 2.07 percent and body weight by seven to nine-and-a-half kilograms over forty weeks, with no excess hypoglycaemia [1]. In SURPASS-2, the same three doses, added to metformin, were noninferior and superior to once-weekly semaglutide one milligram for HbA1c reduction; the fifteen-milligram arm produced nearly twice the weight loss of semaglutide one milligram [2]. In the obesity programme, SURMOUNT-1 enrolled adults with obesity or overweight and at least one weight-related comorbidity and reported mean body-weight reductions of sixteen, 21.4, and 22.5 percent at five, ten, and fifteen milligrams against 2.4 percent on placebo at seventy-two weeks; eighty-nine to ninety-six percent of treated participants lost at least five percent of baseline body weight, compared with twenty-eight percent on placebo [3]. The 2025 SURMOUNT-5 head-to-head trial then placed tirzepatide directly against semaglutide 2.4 milligrams for chronic weight management in adults with obesity without diabetes: 20.2 percent mean weight reduction with tirzepatide versus 13.7 percent with semaglutide at seventy-two weeks, a relative difference of forty-seven percent [9]. ## Beyond glycaemia and weight The newer trials extend the cabinet beyond the original endocrine indications. SUMMIT enrolled adults with heart failure with preserved ejection fraction and obesity and reported a thirty-eight percent relative reduction in the composite of cardiovascular death or worsening heart failure over a median two years, with measurable reductions in left-ventricular mass and paracardiac adipose tissue [6]. SURMOUNT-OSA evaluated tirzepatide at ten and fifteen milligrams in adults with moderate-to-severe obstructive sleep apnoea and obesity and reported reductions in apnoea-hypopnoea index of approximately twenty-five to twenty-nine events per hour, against roughly five events per hour with placebo, at fifty-two weeks — measured across cohorts both on and off positive-airway-pressure therapy [7]. SYNERGY-NASH, in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis and stage two or three fibrosis, reported that 51.8, 62.8, and 73.3 percent of participants on five, ten, and fifteen milligrams of tirzepatide achieved resolution of steatohepatitis without worsening fibrosis at fifty-two weeks, against 13.2 percent on placebo [8]. A post-hoc SURPASS-4 analysis observed an approximately fifty-percent lower risk of a composite kidney endpoint compared with insulin glargine over a median follow-up of eighty-five to one-hundred-and-four weeks [10], and a pooled SURPASS-1 through 5 analysis recorded systolic blood-pressure reductions of approximately 4.2 to 5.8 millimetres of mercury, dose-dependently [11]. ### Boxed warning A boxed warning in the FDA label addresses the risk of thyroid C-cell tumours, derived from rodent two-year carcinogenicity studies. The human relevance is unconfirmed, but the label contraindication is unambiguous in subjects with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome. ## Why this cabinet exists Get Tirzepatide is an independent editorial project. It does not sell tirzepatide. It does not employ clinicians. It does not write prescriptions. Its only labour is curatorial: to take a clinical record that now spans more than a dozen named phase-three trials and present it with the ceremony that the evidence warrants, one cabinet at a time. Where other readers might encounter the literature as fragments — a press release here, a press release there, a brand name everywhere — the cabinets here favour the underlying compound, the underlying trial protocols, and the figures that survive peer review. The pages that follow group the record into four cabinets. The research cabinet walks the trial programme. The dosage cabinet collates the label-aligned titration ladder and the pharmacokinetic figures that underwrite it. The frequently-asked-questions cabinet handles the recurring confusions. The references cabinet holds the primary sources, fully cited. Throughout, the writing is editorial and the disclaimer is plain: tirzepatide is a regulated prescription medicine. Material discussed on this site is not for human consumption, and nothing on this site is medical advice. ## References [1] Rosenstock J, et al. SURPASS-1. The Lancet. 2021. DOI: 10.1016/S0140-6736(21)01324-6 [2] Frias JP, et al. Tirzepatide vs Semaglutide. NEJM. 2021. DOI: 10.1056/NEJMoa2107519 [3] Jastreboff AM, et al. Tirzepatide for Obesity (SURMOUNT-1). NEJM. 2022. DOI: 10.1056/NEJMoa2206038 [4] Willard FS, et al. Imbalanced and biased dual GIP/GLP-1 agonist. JCI Insight. 2020. DOI: 10.1172/jci.insight.140532 [5] Schneck KB, et al. Population PK of tirzepatide. CPT:PSP. 2024. DOI: 10.1002/psp4.13099 [6] Packer M, et al. Tirzepatide for HFpEF (SUMMIT). NEJM. 2024. DOI: 10.1056/NEJMoa2410027 [7] Malhotra A, et al. Tirzepatide for OSA (SURMOUNT-OSA). NEJM. 2024. DOI: 10.1056/NEJMoa2404881 [8] Loomba R, et al. Tirzepatide for MASH (SYNERGY-NASH). NEJM. 2024. DOI: 10.1056/NEJMoa2401943 [9] Aronne LJ, et al. Tirzepatide vs Semaglutide (SURMOUNT-5). NEJM. 2025. DOI: 10.1056/NEJMoa2416394 [10] Heerspink HJL, et al. SURPASS-4 kidney outcomes. The Lancet D&E. 2022. DOI: 10.1016/S2213-8587(22)00243-1 [11] de Boer IH, et al. Systolic BP reduction (SURPASS pooled). Cardiovasc Diabetol. 2023. DOI: 10.1186/s12933-023-01775-x --- Not medical advice. This site does not sell any product and is not affiliated with any vendor or manufacturer.